Cumulative studies indicate that CDCA3 is abnormally high expressed in multiple human malignancies, such as glioma (Han et al., 2024), prostate cancer (Gu et al., 2023), pan-renal cell carcinoma (Luo et al., 2024), and bladder cancer (Shen et al., 2025), which may contribute to tumor progression as an oncogene. Here, CDCA3 is linked to renal cell carcinoma.